F&S reports · 2022
Perinatal outcomes and congenital anomalies associated with letrozole and natural cycles in single fresh cleaved embryo transfers: A single-center, 10-year cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takeshima Kazumi, Ezoe Kenji, Kawasaki Nami, Hayashi Hiroko, Kuroda Tomoko, Kato Keiichi
Аннотация
OBJECTIVE: To investigate and compare the safety of letrozole and natural cycles in fresh early embryo transfers.
DESIGN: A retrospective cohort study.
SETTING: A large fertility treatment center.
PATIENTS: Women who underwent natural and letrozole cycles during fresh early embryo transfer at Kato Ladies Clinic between January 2008 and December 2017.
INTERVENTIONS: None.
MAIN OUTCOME MEASURES: Perinatal complications and congenital anomalies.
RESULTS: No significant differences were observed in pregnancy complications, gestational age, birth weight, small for gestational age, large for gestational age, and congenital anomalies between the the women who underwent natural and letrozole cycles.
CONCLUSIONS: The perinatal outcomes and congenital anomaly rates associated with letrozole and natural cycles in fresh early embryo transfers were comparable. Therefore, our data support the safe use of letrozole in fresh early embryo transfers in assisted reproductive technology.
DESIGN: A retrospective cohort study.
SETTING: A large fertility treatment center.
PATIENTS: Women who underwent natural and letrozole cycles during fresh early embryo transfer at Kato Ladies Clinic between January 2008 and December 2017.
INTERVENTIONS: None.
MAIN OUTCOME MEASURES: Perinatal complications and congenital anomalies.
RESULTS: No significant differences were observed in pregnancy complications, gestational age, birth weight, small for gestational age, large for gestational age, and congenital anomalies between the the women who underwent natural and letrozole cycles.
CONCLUSIONS: The perinatal outcomes and congenital anomaly rates associated with letrozole and natural cycles in fresh early embryo transfers were comparable. Therefore, our data support the safe use of letrozole in fresh early embryo transfers in assisted reproductive technology.